Ardena has officially completed the divestment of its drug substance manufacturing facility located in Sweden to Nanologica, marking a significant shift in its operational focus. This strategic move allows Ardena to concentrate more deeply on its core competencies in drug development and analytical services, while Nanologica plans to expand its footprint in the pharmaceutical manufacturing sector through this acquisition. The transfer includes all physical assets, intellectual property, and key personnel associated with the site, ensuring continuity and a seamless transition for ongoing projects.

The acquisition is poised to enhance Nanologica’s capabilities in high-quality drug substance production, supporting its ambition to grow within the Scandinavian pharmaceutical market. Key highlights of the deal include:

  • Site Location: Gothenburg, Sweden
  • Workforce Transfer: Over…